Autoimmune Encephalitis Clinical Trials

24 recruitingLast updated: June 18, 2026

There are 24 actively recruiting autoimmune encephalitis clinical trials across 21 countries. Studies span Phase 2, Early Phase 1, Not Applicable, Phase 1, Phase 3. Top locations include Wuhan, Hubei, China, Bron, France, Paris, France. Updated daily from ClinicalTrials.gov.


Autoimmune Encephalitis Trials at a Glance

24 actively recruiting trials for autoimmune encephalitis are listed on ClinicalTrialsFinder across 6 cities in 21 countries. The largest study group is Phase 2 with 5 trials, with the heaviest enrollment activity in Wuhan, Bron, and Paris. Lead sponsors running autoimmune encephalitis studies include Tongji Hospital, Hospices Civils de Lyon, and Brain Inflammation Collaborative.

Browse autoimmune encephalitis trials by phase

Treatments under study

About Autoimmune Encephalitis Clinical Trials

Looking for clinical trials for Autoimmune Encephalitis? There are currently 16 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Autoimmune Encephalitis trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Autoimmune Encephalitis clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 24 trials

Recruiting

Cohort Study on Neuroimmune Diseases in the Reproductive Age

Myasthenia GravisAutoimmune EncephalitisMultiple Sclerosis+3 more
Third Affiliated Hospital, Sun Yat-Sen University100 enrolled1 locationNCT07653984
Recruiting
Phase 3

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) Encephalitis

NMDAR Autoimmune EncephalitisLGI1 Autoimmune Encephalitis
Hoffmann-La Roche120 enrolled93 locationsNCT05503264
Recruiting
Early Phase 1

CD19/BCMA-Targeted UCAR-T for Patients With Neurological Autoimmune Diseases

Relapsing or Refractory Multiple Sclerosis (MS)Myasthenia Gravis (MG)Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)+1 more
Tongji Hospital36 enrolled1 locationNCT07337785
Recruiting
Phase 2

A Study in Participants With Anti-NMDAR Encephalitis and Anti-NMDAR Autoantibody-Associated Psychiatric Disease

Autoimmune EncephalitisAnti-N-methyl-D-aspartate Receptor (NMDAR) Encephalitis (ANRE)Anti-N-methyl-D-aspartate Receptor (NMDAR) Antibody-associated Psychiatric Disease
Arialys Australia Pty Ltd30 enrolled1 locationNCT07093333
Recruiting
Phase 1

Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.

Neuromyelitis Optica Spectrum Disorder (NMOSD)Multiple Sclerosis (MS)Myasthenia Gravis (MG)+4 more
Tongji Hospital6 enrolled1 locationNCT07526493
Recruiting
Phase 2

Is [18F]-DPA-714 PET a Good Marker of Neuroinflammation in Autoimmune Encephalitis?

Autoimmune Encephalitis (AE)
University Hospital, Toulouse40 enrolled1 locationNCT07488117
Recruiting

FDG-PET in the Diagnosis of Autoimmune Encephalitis

Autoimmune Encephalitis
University of Milano Bicocca90 enrolled6 locationsNCT06019975
Recruiting

Study of Pathogenic Mechanisms and Identification of Novel Autoantibodies in Autoimmune Encephalitis

Autoimmune Encephalitis
Fondazione Policlinico Universitario Agostino Gemelli IRCCS20 enrolled1 locationNCT07477015
Recruiting

Long-term Impact of NMDAR Encephalitis, Level 3

NMDAR Autoimmune Encephalitis
Hospices Civils de Lyon30 enrolled1 locationNCT07158229
Recruiting

Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research

Traumatic Brain InjuryEhlers-Danlos SyndromePost-Acute COVID-19 Syndrome+41 more
Brain Inflammation Collaborative10,000 enrolled1 locationNCT04806620
Recruiting
Early Phase 1

Universal Chimeric Antigen Receptor T-Cell (UCAR T-cell) Therapy Targeting CD19/B Cell Maturation Antigen (CD19/BCMA) in Patients With r/r Neurological Autoimmune Diseases

Myasthenia GravisAutoimmune EncephalitisMultiple Sclerosis+2 more
Tianjin Huanhu Hospital12 enrolled1 locationNCT06939166
Recruiting
Phase 2

Trial to Evaluate Efficacy and Safety of Bortezomib in Patients With Severe Autoimmune Encephalitis

Autoimmune Encephalitis
Jena University Hospital50 enrolled17 locationsNCT03993262
Recruiting
Not Applicable

Impact of Confirmed Autoimmune Encephalitis on Brain Glucose Metabolism

Autoimmune Encephalitis
Assistance Publique - Hôpitaux de Paris56 enrolled1 locationNCT06079294
Recruiting

A Prospective Study to Evaluate Clinical Outcomes in Anti-LGI1 Encephalitis

Autoimmune EncephalitisLeucine-Rich Glioma Inactivated 1 Autoimmune Encephalitis
Shen Chun-Hong60 enrolled1 locationNCT06173076
Recruiting

Medium-term Effects of Treatments in Autoimmune Encephalitis

GFAPNMDAR Autoimmune EncephalitisLGI1 Antibody Associated Encephalitis+3 more
Hospices Civils de Lyon200 enrolled1 locationNCT07133113
Recruiting
Phase 2

The ExTINGUISH Trial of Inebilizumab in NMDAR Encephalitis

EncephalitisAutoimmune Encephalitis
University of Utah116 enrolled39 locationsNCT04372615
Recruiting
Not Applicable

Efficacy and Safety of Calculus Bovis Sativus (CBS) for Adult Encephalitis (CBSinEncephalitis)

EncephalitisAutoimmune EncephalitisEncephalitis, Viral+1 more
Tongji Hospital250 enrolled1 locationNCT06584045
Recruiting
Phase 2

IVIG and Rituximab in Antibody-associated Psychosis - SINAPPS2

Autoimmune EncephalitisPsychosis
University of Cambridge70 enrolled10 locationsNCT03194815
Recruiting

Swiss Pediatric Inflammatory Brain Disease Registry (Swiss-Ped-IBrainD)

Multiple SclerosisOptic NeuritisTransverse Myelitis+15 more
University of Bern500 enrolled13 locationsNCT05017142
Recruiting

Biomarkers in Autoimmune Disease of Nervous System

Myasthenia GravisAutoimmune EncephalitisMultiple Sclerosis+8 more
Tongji Hospital50,000 enrolled1 locationNCT06502015